114 related articles for article (PubMed ID: 38528728)
41. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
Shah AM; Shah SJ; Anand IS; Sweitzer NK; O'Meara E; Heitner JF; Sopko G; Li G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD;
Circ Heart Fail; 2014 Jan; 7(1):104-15. PubMed ID: 24249049
[TBL] [Abstract][Full Text] [Related]
42. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
[TBL] [Abstract][Full Text] [Related]
43. Association of Active and Passive Components of LV Diastolic Filling With Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Mechanistic Insights From Spironolactone Response.
Kosmala W; Przewlocka-Kosmala M; Marwick TH
JACC Cardiovasc Imaging; 2019 May; 12(5):784-794. PubMed ID: 29248640
[TBL] [Abstract][Full Text] [Related]
44. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.
Tsutamoto T; Wada A; Maeda K; Mabuchi N; Hayashi M; Tsutsui T; Ohnishi M; Sawaki M; Fujii M; Matsumoto T; Matsui T; Kinoshita M
J Am Coll Cardiol; 2001 Apr; 37(5):1228-33. PubMed ID: 11300427
[TBL] [Abstract][Full Text] [Related]
45. Plasma NT-proBNP levels associated with cardiac structural abnormalities in asymptomatic health examinees with preserved ejection fraction: a retrospective cross-sectional study.
Nah EH; Kim SY; Cho S; Kim S; Cho HI
BMJ Open; 2019 Apr; 9(4):e026030. PubMed ID: 31005928
[TBL] [Abstract][Full Text] [Related]
46. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.
Kristensen SL; Jhund PS; Mogensen UM; Rørth R; Abraham WT; Desai A; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV;
Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29018174
[TBL] [Abstract][Full Text] [Related]
47. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
[TBL] [Abstract][Full Text] [Related]
48. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.
McKelvie RS; Komajda M; McMurray J; Zile M; Ptaszynska A; Donovan M; Carson P; Massie BM;
J Card Fail; 2010 Feb; 16(2):128-34. PubMed ID: 20142024
[TBL] [Abstract][Full Text] [Related]
49. IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure.
Januzzi JL; Packer M; Claggett B; Liu J; Shah AM; Zile MR; Pieske B; Voors A; Gandhi PU; Prescott MF; Shi V; Lefkowitz MP; McMurray JJV; Solomon SD
Circ Heart Fail; 2018 Oct; 11(10):e005133. PubMed ID: 30354399
[TBL] [Abstract][Full Text] [Related]
50. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
[TBL] [Abstract][Full Text] [Related]
51. Left atrial deformation and nonischemic dilated cardiomyopathy. A 2D speckle-tracking imaging study.
Guler A; Tigen KM; Dundar C; Karaahmet T; Karabay CY; Aung SM; Akgun T; Bulut M; Kirma C
Herz; 2014 Mar; 39(2):251-7. PubMed ID: 23649320
[TBL] [Abstract][Full Text] [Related]
52. NT-proBNP and Echocardiographic Parameters for Prediction of Cardiovascular Outcomes in Patients with CKD Stages G2-G4.
Untersteller K; Girerd N; Duarte K; Rogacev KS; Seiler-Mussler S; Fliser D; Rossignol P; Heine GH
Clin J Am Soc Nephrol; 2016 Nov; 11(11):1978-1988. PubMed ID: 27515593
[TBL] [Abstract][Full Text] [Related]
53. Association between the N-terminal plasma brain natriuretic peptide levels or elevated left ventricular filling pressure and thromboembolic risk in patients with non-valvular atrial fibrillation.
Yu GI; Cho KI; Kim HS; Heo JH; Cha TJ
J Cardiol; 2016 Aug; 68(2):110-6. PubMed ID: 26775889
[TBL] [Abstract][Full Text] [Related]
54. Relation of natriuretic peptides and midregional proadrenomedullin to cardiac chamber volumes by computed tomography in patients without heart failure: from the ROMICAT Trial.
Truong QA; Siegel E; Karakas M; Januzzi JL; Bamberg F; Mahabadi AA; Dasdemir S; Brady TJ; Bergmann A; Kunde J; Nagurney JT; Hoffmann U; Koenig W
Clin Chem; 2010 Apr; 56(4):651-60. PubMed ID: 20185624
[TBL] [Abstract][Full Text] [Related]
55. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
[TBL] [Abstract][Full Text] [Related]
56. Determinants of the beneficial effect of mineralocorticoid receptor antagonism on exercise capacity in heart failure with reduced ejection fraction.
Dankowski R; Kotwica T; Szyszka A; Przewłocka-Kosmala M; Sacharczuk W; Karolko B; Kobusiak-Prokopowicz M; Mysiak A; Kosmala W
Kardiol Pol; 2018; 76(9):1327-1335. PubMed ID: 29862486
[TBL] [Abstract][Full Text] [Related]
57. Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction.
de Denus S; Lavoie J; Ducharme A; O'Meara E; Racine N; Sirois MG; Neagoe PE; Zhu L; Rouleau JL; White M
Can J Cardiol; 2012; 28(1):62-8. PubMed ID: 22104539
[TBL] [Abstract][Full Text] [Related]
58. Atrial Cardiopathy Biomarkers and MRI-Based Infarct Patterns in Patients with Embolic Strokes of Undetermined Source.
Lee YK; Gwak BC; Yoon BA; Kim DH; Cha JK
J Stroke Cerebrovasc Dis; 2021 Aug; 30(8):105933. PubMed ID: 34157668
[TBL] [Abstract][Full Text] [Related]
59. Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone.
Cohen JB; Schrauben SJ; Zhao L; Basso MD; Cvijic ME; Li Z; Yarde M; Wang Z; Bhattacharya PT; Chirinos DA; Prenner S; Zamani P; Seiffert DA; Car BD; Gordon DA; Margulies K; Cappola T; Chirinos JA
JACC Heart Fail; 2020 Mar; 8(3):172-184. PubMed ID: 31926856
[TBL] [Abstract][Full Text] [Related]
60. Prognostic role of left atrial volume in elderly patients with symptomatic stable chronic heart failure: comparison with left ventricular diastolic dysfunction and B-type natriuretic peptide.
Popescu BA; Popescu AC; Antonini-Canterin F; Rubin D; Cappelletti P; Piazza R; Ginghina C; Dimulescu D; Beladan CC; Nicolosi GL
Echocardiography; 2007 Nov; 24(10):1035-43. PubMed ID: 18001356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
